[ 1 ] Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21[J]. Science, 1990, 250(4988): 1684-1689.
[2]
[ 2 ] Wilson KA, Stern DF. NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway[J]. Cell Cycle, 2008, 7(22): 3584-3594.
[3]
[ 3 ] Judith EC, Jennifer EQ, Caroline OM, et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer[J]. Gynecologic Oncology, 2011, 3(123): 492-498.
[4]
[ 4 ] Squatrito M, Vanoli F, Schultz N, et al. 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma[J].Cancer Res, 2012, 72(20): 5250-5260.
[5]
[ 5 ] Patel AN, Goyal S, Wu H, et al. Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy[J]. Breast Cancer Res Treat, 2010, 126(3): 601-607.
[6]
[ 6 ] Roossink F, Wieringa HW, Noordhuis MG, et al. The role of ATM and 53BP1 as predictive markers in cervical cancer[J]. Int J Cancer, 2012, 131(9): 2056-2066.
[7]
[ 7 ] Su C, Zhou S, Zhang L, et al. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer[J]. Med Oncol, 2011, 28(4): 1411-1417.
[8]
[ 8 ] Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer[J]. Asian J Androl, 2012, 14(3): 409-414.
[9]
[ 9 ] Mullan PB, Quinn JE, Gilmore PM, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents[J]. Oncogene, 2001, 20(43): 6123-6131.
[10]
Yarden RI, Pardo-Reoyo S, Sgagias M, et al. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage[J]. Nat Genet, 2002, 30(3): 285-289.
[11]
Stewart GS, Wang B, Bignell CR, et al. MDC1 is a mediator of the mammalian DNA damage checkpoint[J]. Nature, 2003, 421(6926): 961-966.
[12]
Peng A, Chen PL. NFBD1/Mdc1 mediates ATR-dependent DNA damage response[J]. Cancer Res, 2005, 65(4): 1158-1163.
[13]
Bartek J, Falck J, Lukas J. CHK2 kinase a busy messenger[J]. Nat Rev Mol Cell Biol, 2001, 2(12): 877-886.
[14]
Ward IM, Minn K, Jorda KG, et al. Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX[J]. Biol Chem, 2003, 278(22): 19579-19582.
[15]
Scully R, Puget N. BRCA1 and BRCA2 in hereditary breast cancer[J]. Biochimie, 2002, 84(1): 95-102.
[16]
Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk[J]. Br J Cancer, 2012, 106(10): 1697-1701.
[17]
Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer[J]. PLoS One, 2007, 2(11): e1129.
Mosconi M, Giesen U, Langner F, et al. 53BP1 and MDC1 foci formation in HT-1080 cells for low- and high-LET microbeam irradiations[J]. Radiat Environ Biophys, 2011, 50(3): 345-352.
[21]
Yuan C, Bu Y, Wang C, et al. NFBD1/MDC1 is a protein of oncogenic potential in human cervical cancer[J]. Mol Cell Biochem, 2012, 359(1-2): 333-346.
[22]
Bu Y, Suenaga Y, Okoshi R, et al. NFBD1/MDC1 participates in the regulation of G2/M transition in mammalian cells[J]. Biochem Biophys Res Commun, 2010, 397(2): 157-162.
[23]
Lou Z, Chini CC, Minter-Dykhouse K, et al. Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control[J]. Biol Chem, 2003, 278(16): 13599-13602.
